



Arytmogenní kardiomyopatie pravé komory

Tomáš Paleček

Centrum pro choroby myokardu a perikardu

II. interní klinika- klinika kardiologie a angiologie

Všeobecná fakultní nemocnice a 1. lékařská fakulta Univerzity Karlovy



Historie arytmogenní kardiomyopatie pravé komory

Giovanni Lancisi
(1654 -1720)

papežský lékař:
Inocenc XI
Klement IX
Inocenc XII

*Popsána rodina s chorobou postihující
obdobnými obtížemi 4 generace:
palpitace, srdeční selhání, náhlou smrt,
dilatace a aneuryzmata pravé komory*



**JOHANNIS MARIAE
LANCISII**

*A Secretiori Cubiculo, & Archiatri
Pontificii*

**DE MOTU CORDIS
ET ANEURYSMATIBUS
OPUS POSTUMUM**

IN DUAS PARTES DIVISUM.



NEAPOLI ANNO dōccccxxviii.
Excudebat FELIX-CAROLUS MUSCA
SUPERIORUM FACULTATE.

Historie arytmogenní kardiomyopatie pravé komory

Right Ventricular Dysplasia: A Report of 24 Adult Cases

MARY Right ventricular dysplasia is characterized by an abnormality in the development of part of right ventricular musculature. Patients with right ventricular dysplasia may present with ventricular tachycardia, supraventricular arrhythmias, right-heart failure or syncope. In 24 patients with right ventricular dysplasia who had recurrent ventricular tachycardia, the male/female ratio was 2.7:1. The mean age at the time of diagnosis was 42 years. In 12 patients had ventricular tachycardia of a left bundle branch type. In 12 patients waves were inverted over the right precordial leads. The left bundle branch type was usually normal. In six patients who had two-dimensional echocardiography and right ventricular diastolic dimensions. All patients had right ventricular angiography. Right ventricular dysplasia was substantiated during surgery in 12 patients and at autopsy in 12 patients who did not have arrhythmias had right ventricular dysplasia diagnosed by angiography.

Corusc FI et al., Circulation **1982**;85

RIGHT VENTRICULAR CARDIOMYOPATHY AND SUDDEN DEATH IN YOUNG PEOPLE

GAETANO THIENE, M.D., ANDREA NAVA, M.D., DOMENICO CORRADO, M.D., LINO ROSSI, M.D.
AND NATALE PENNELLI, M.D.

At autopsy, the subjects' heart weights were normal or moderately increased. Two main histologic patterns were identified — a lipomatous transformation or a fibrolipomatous transformation of the right ventricular free wall (6 cases each); in all cases, the left ventricle was substantially spared. Signs of myocardial degeneration and necrosis, with or without inflammatory infiltrates, were occasionally observed.


These findings indicate that right ventricular cardiomyopathy, the cause of which is still unknown, may be more frequent than previously thought. At least in this area of Italy, it may represent an important cause of sudden death among young people. (N Engl J Med 1988; 318:129-33.)

Thiene G et al., NEJM **1988**;318




ARVC ~ jeden ze základních fenotypů KMP

= definována jako přítomnost **dominantní dilatace a/nebo dysfunkce pravé komory** v kombinaci s **histologickým průkazem choroby a/nebo EKG abnormalitami** podle modifikovaných diagnostických kritérií z roku 2010





Fenotypy KMP: ACM vs. ARVC





Arytmogenní kardiomyopatie pravé komory

strukturálně charakterizována **progresivní náhradou myokardu pravé komory**
fibrotickou / fibrolipomatózní tkání (možné postižení i LK), **od epikardu k endokardu**

obvykle se manifestuje ve 2.-4 dekadě života, častěji muži (60%)

geneticky podmíněná: většinou **AD typ dědičnosti**

penetrance ~ věk (pohlaví, fyzická aktivita)


mutační varianty v **genech kódujících**

desmosomální proteiny (PKP2, DSG2, DSP, DSC2, JUP)

nebo v non-desmosomálních genech (TMEM43, DES, PLN...)

pozitivní genetická diagnostika až v 60% případů

prevalence cca 1:2,5000-5000 (~ geografická závislost)






ARVC: klinická prezentace

palpitace

synkopy

náhlá zástava oběhu / SCD



četné komorové extrasystoly

nesetrvalé / setrvalé běhy KT

fibrilace komor

zřídka srdeční selhání

komorová systolická dysfunkce

bolestivá myokarditis

hot fáze choroby

(! myslet u rekurentních myokarditid)



ARVC: diagnostika

Proposed Modification of the Task Force Criteria

Globální/regionální dysfunkce a strukturální alterace pra
(echokg, MRI, invazivní ventrikulografie PK)

káňová charakteristika stěny PK (EMB, postmortem)

KG repolarizační abnormality

KG depolarizační / převodní abnormality

rytmie (NSVT, SVT, KES)

odinná anamnéza, genetika

Definitivní diagnóza ARVC:

2 velká kritéria

1 velké + 2 malá kritéria

4 malá kritéria

Hraniční diagnóza ARVC:

1 velké a 1 malé kritérium

3 malá kritéria

Možná diagnóza ARVC:

1 velké kritérium

2 malá kritéria



ARVC: diagnostika

Proposed Modification of the Task Force Criteria


Tkáňová charakteristika stěny PK (EMB, postmortem)

Velké kritérium

Residual myocytes **<60%** by morphometric analysis (or **<50%** if estimated), **with fibrous replacement of the RV free wall** myocardium in ≥ 1 sample, with or without fatty replacement of tissue on endomyocardial biopsy

Malé kritérium

Residual myocytes **60% to 75%** by morphometric analysis (or **50% to 65%** if estimated), **with fibrous replacement of the RV free** wall myocardium in ≥ 1 sample, with or without fatty replacement of tissue on endomyocardial biopsy



Ideálně EMB navigovaná elektroanatomickým voltážovým mapováním



ARVC: diagnostika

Proposed Modification of the Task Force Criteria

Rodinná anamnéza, genetika

Velké kritérium

ARVC/D confirmed in a first-degree relative who meets current TFC

ARVC/D confirmed pathologically at autopsy or surgery in a first-degree relative

Identification of a pathogenic mutation categorized as associated or probably associated with ARVC/D in the patient

Malé kritérium

History of ARVC/D in a first-degree relative in whom it is not possible or practical to determine whether the family member meets current TFC

Premature sudden death (<35 yrs of age) due to suspected ARVC/D in a first-degree relative

ARVC/D confirmed pathologically or by current TFC in second-degree relative



ARVC: diagnostika

Proposed Modification of the Task Force Criteria


EKG – depolarizační změny

Velké kritérium

epsilon wave in the right precordial leads (V₁ to V₃)

Malé kritérium

potentials by SAEKG in ≥ 1 of 3 parameters in the presence of a QRS duration ≥ 110 ms on the standard ECG
prolonged QRS duration ≥ 114 ms
duration of terminal QRS < 40 μ V (low-amplitude signal duration) ≥ 38 ms
root mean square voltage of terminal 40 ms ≤ 20 μ V
terminal activation duration of QRS ≥ 55 ms measured from nadir of the S-wave to the end of the QRS, including R', in V₁, V₂, or V₃, in the absence of complete RBBB





ARVC: diagnostika

Proposed Modification of the Task Force Criteria


EKG – repolarizační změny

Velké kritérium

Upravené T vlny v pravých precardiálních vodičích (V_1 , V_2 , a V_3) nebo dále v jednotlivých >14 let věku (v nepřítomnosti úplné RBBB QRS ≥ 120 ms)

Malé kritérium

Upravené T vlny v vodičích V_1 a V_2 u jednotlivých >14 let věku (v nepřítomnosti úplné RBBB) nebo v V_4 , V_5 , nebo V_6
Upravené T vlny v vodičích V_1 , V_2 , V_3 , a V_4 u jednotlivých ≤ 14 let věku v přítomnosti úplné RBBB





ARVC: diagnostika

Proposed Modification of the Task Force Criteria


Arytmie

Velké kritérium

Unsustained or sustained VT of LBBB morphology with superior axis (negative or indeterminate QRS in leads II, III, and aVF and positive in lead aVL)

Malé kritérium

Unsustained or sustained RVOT VT of LBBB morphology with superior axis (positive QRS in leads II, III, and aVF and negative in lead aVL) or with unknown axis
100 ventricular extrasystoles per 24 h (Holter)






ARVC: diagnostika - echokardiografie

Proposed Modification of the Task Force Criteria

- regionální akineze / dyskineze / aneuryzma PK (!ne hypokineze)
- dilatace PK, snížená FAC PK



By 2D echo:

Velké kritérium

- Regional RV akinesia, dyskinesia, or aneurysm
- *and* 1 of the following (end diastole):
 - PLAX RVOT ≥ 32 mm (corrected for body size [PLAX/BSA] ≥ 19 mm/m²)
 - PSAX RVOT ≥ 36 mm (corrected for body size [PSAX/BSA] ≥ 21 mm/m²)
 - *or* fractional area change $\leq 33\%$

Malé kritérium


- Regional RV akinesia or dyskinesia
- *and* 1 of the following (end diastole):
 - PLAX RVOT ≥ 29 to < 32 mm (corrected for body size [PLAX/BSA] ≥ 16 to < 19 mm/m²)
 - PSAX RVOT ≥ 32 to < 36 mm (corrected for body size [PSAX/BSA] ≥ 18 to < 21 mm/m²)
 - *or* fractional area change $> 33\%$ to $\leq 40\%$



ARVC: diagnostika - echokardiografie

Proposed Modification of the Task Force Criteria

- regionální akineze / dyskineze / aneuryzma PK (! ne hypokineze)
- dilatace PK, snížená FAC PK



By 2D echo:

- Regional RV akinesia, dyskinesia, or aneurysm
- *and* 1 of the following (end diastole):
 - PLAX RVOT ≥ 32 mm (corrected for body size [PLAX/BSA] ≥ 19 mm/m²)
 - PSAX RVOT ≥ 36 mm (corrected for body size [PSAX/BSA] ≥ 21 mm/m²)
 - *or* fractional area change $\leq 33\%$

Velké kritérium

- Regional RV akinesia or dyskinesia
- *and* 1 of the following (end diastole):
 - PLAX RVOT ≥ 29 to < 32 mm (corrected for body size [PLAX/BSA] ≥ 16 to < 19 mm/m²)
 - PSAX RVOT ≥ 32 to < 36 mm (corrected for body size [PSAX/BSA] ≥ 18 to < 21 mm/m²)
 - *or* fractional area change $> 33\%$ to $\leq 40\%$


Malé kritérium



ARVC: diagnostika - echokardiografie

Proposed Modification of the Task Force Criteria

- regionální akineze / dyskineze / aneuryzma PK (! ne hypokineze)
- dilatace PK, snížená FAC PK



Obrazový archiv VFN

By 2D echo:

- Regional RV akinesia, dyskinesia, or aneurysm
- *and* 1 of the following (end diastole):
 - PLAX RVOT ≥ 32 mm (corrected for body size [PLAX/BSA] ≥ 19 mm/m²)
 - PSAX RVOT ≥ 36 mm (corrected for body size [PSAX/BSA] ≥ 21 mm/m²)
 - *or* fractional area change $\leq 33\%$

Velké kritérium

- Regional RV akinesia or dyskinesia
- *and* 1 of the following (end diastole):
 - PLAX RVOT ≥ 29 to < 32 mm (corrected for body size [PLAX/BSA] ≥ 16 to < 19 mm/m²)
 - PSAX RVOT ≥ 32 to < 36 mm (corrected for body size [PSAX/BSA] ≥ 18 to < 21 mm/m²)
 - *or* fractional area change $> 33\%$ to $\leq 40\%$


Malé kritérium



ARVC: diagnostika - echokardiografie

lokální akineze / aneuryzma PK
→ **modifikované či netradiční projekce na PK!**

Projekce na vtok PK



Obrazový archiv VFN



The diagnostic performance of imaging methods in ARVC using the 2010 Task Force criteria

MRI = u ARVC zobrazovací metoda první volby

criteria by echocardiography or CMR (as defined by 2010 Task Force criteria)

	CMR negative	CMR positive	Total
Echocardiography negative (<i>n</i>)	21	36	57
Echocardiography positive (<i>n</i>)	9	36	45
Total	30	72	102

Diagnostic performance for echocardiography when compared with CMR. PPV 80%, NPV 37%, sensitivity 50% and specificity 70%. $P = 0.06$.



ARVC: diagnostika - MRI

Proposed Modification of the Task Force Criteria

- regionální akineze / dyskineze / aneuryzma PK (! ne hypokineze)
- dilatace PK, snížená FAC PK
- není zahrnuto LGE (tkáňová charakteristika) !



Velké kritérium

By MRI:

- Regional RV akinesia or dyskinesia or dyssynchronous RV contraction
- *and* 1 of the following:
 - Ratio of RV end-diastolic volume to BSA ≥ 110 mL/m² (male) or ≥ 100 mL/m² (female)
 - *or* RV ejection fraction $\leq 40\%$

Malé kritérium

- Regional RV akinesia or dyskinesia or dyssynchronous RV contraction
- *and* 1 of the following:
 - Ratio of RV end-diastolic volume to BSA ≥ 100 to < 110 mL/m² (male) or ≥ 90 to < 100 mL/m² (female)
 - *or* RV ejection fraction $> 40\%$ to $\leq 45\%$



ARVC: diagnostika – Padovská kritéria ACM

kritéria pro ARVC

Morpho-functional
ventricular abnormalities

Major

- Regional RV akinesia, dyskinesia, or bulging *plus* one of the following:
 - Global RV dilatation (increase of RV EDV according to the imaging test specific nomograms for age and sex)
 - Global RV systolic dysfunction (reduction of RV EF according to the imaging test specific nomograms for age and sex)

Minor

- Regional RV akinesia, dyskinesia, or aneurysm of RV free wall

Structural myocardial
abnormalities

Major

- Transmural LGE (stria pattern) of ≥ 1 RV region(s) (inlet, outlet, and apex in two orthogonal views)

Major

- Fibrous replacement of the myocardium in ≥ 1 sample, with or without fatty tissue

Major

- Inverted T waves in right precordial leads (V_1 , V_2 , and V_3) or beyond in individuals with complete pubertal development (in the absence of complete RBBB)


Minor

- Inverted T waves in leads V_1 and V_2 in individuals with completed pubertal development (in the absence of complete RBBB)
- Inverted T waves in V_1 , V_2 , V_3 , and V_4 in individuals with completed pubertal development in the presence of complete RBBB

IV. Depolarization
abnormalities

Minor

- Epsilon wave (reproducible low-amplitude signals between end of QRS complex to onset of the T wave) in the right precordial leads (V_1 to V_3)
- Terminal activation duration of QRS ≥ 55 ms measured from the nadir of the S wave to the end of the QRS (including R', in V_1 , V_2 , or V_3 complete RBBB)



extrasystoles (>500 per
or sustained ventricular
morphology

extrasystoles (>500 per
or sustained ventricular
morphology with inferior

Depolarization
abnormalities

ative who meets diagnostic criteria
opsy or surgery in a first-degree relative
ely pathogenetic ACM mutation in the patient under

ative in whom it is not possible or practical to determine
ic criteria

s of age) due to suspected ACM in a first-degree relative

- ACM confirmed pathologically or by diagnostic criteria in second-degree relative



ARVC: diagnostika – význam EKG !

nejčasnější manifestace ~ obvykle EKG změny



strukturální abnormality ~ echokg, MRI

**diagnóza založená jen na zobrazovacích metodách, s
kompletně normálním EKG
⇒ podezřelé ...**



ARVC: management

- ✓ zabránit progresi choroby
- ✓ ovlivnit symptomy
- ✓ zabránit komplikacím ~ prevence SCD (sekundární, primární)




ARVC ~ jedna z nejčastějších příčin SCD
u mladých jedinců, zvláště sportovců

ARVC: prevence progrese choroby


restrikce sportovní zátěže ! ~ redukce progrese již diagnostikované choroby (KT, srdeční selhání)

~ oddálení fenotypické exprese u G+/P- jedinců

< 650 MET hodin/rok ~ 30 minut svižné chůze denně



James CA et al., JACC 2013;62




Wang W et al., Europace 2020;22

ARVC: ovlivnění symptomů - antiarytmika

Safety and efficacy of flecainide associated with beta-blockers in arrhythmogenic right ventricular cardiomyopathy


Nolan CJ et al, EurACC 2009, 22:24 CI 95% p-value



Recommendations	Class ^a	Level
Beta-blocker therapy is recommended in ARVC patients with VE, NSVT, and VT. ⁹²⁰⁻⁹²²	I	C
Amiodarone should be considered when regular beta-blocker therapy fails to control arrhythmia-related symptoms in patients with ARVC. ^{921,922}	IIa	C
Flecainide in addition to beta-blockers should be considered when single agent treatment has failed to control arrhythmia-related symptoms in patients with ARVC. ^{923,924}	IIa	C
Catheter ablation with availability for epicardial approach guided by 3D electroanatomical mapping of VT should be considered in ARVC patients with incessant VT or frequent appropriate ICD interventions for VT despite pharmacological therapy with beta-blockers. ^{925,929-934}	IIa	C

ARVC: prevence SCD (~ implantace ICD)

- ✓ **Známky vysokého rizika:**
- synkopa (arytmická)
 - nesetrválá KT
 - EF pravé komory < 40%
 - EF levé komory < 45%
 - indukovatelná setrválá monomorfní KT při EFS




Recommendations	Class ^a	Level ^b
Secondary prevention		
An ICD is recommended to reduce the risk of sudden death and all-cause mortality in patients with ARVC who have survived a cardiac arrest or have recovered from a ventricular arrhythmia causing haemodynamic instability. ^{939,943,944,948,949}	I	A
An ICD should be considered in ARVC patients who have suffered a haemodynamically tolerated VT. ^{522,939,943-945,948-950}	Ila	B
Primary prevention		
High-risk features ^c should be considered to aid individualized decision-making for ICD implantation in patients with ARVC. ^{538,939}	Ila	B
The updated 2019 ARVC risk calculator should be considered to aid individualized decision-making for ICD implantation in patients with ARVC. ^{d,524,526,536-539}	Ila	B



A new prediction model for ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy

528 jedinců s definitivní dg. ARVC, bez anamnézy setrvalé KT či SCD, 5 registrů v EU a USA


Prediction of sustained ventricular arrhythmia in ARVC



Model for 5-year risk prediction

Sex	x	0.49
Age	x	-0.022
Recent syncope	x	0.66
Non-sustained VT	x	0.81
Ln(24h PVC count)	x	0.17
Leads with T-wave inv.	x	0.11
RVEF	x	-0.025

$$1 - 0.8396^{\exp(\dots)} = 5 \text{ year risk}$$





ARVC: kalkulátor rizika

<https://arvcrisk.com>

at diagnosis

t which the patient fulfilled ARVC diagnosis as per 2010 Task Force
ia (Marcus et al. 2010)

ale

Female

diac syncope (<6 months)

s No

pe suspected to be caused by cardiac arrhythmia within 6 months prior to
osis.

◆ Number of inverted T-waves

0

Total number of precordial and inferior leads with inverted T-waves on
standard 12-lead ECG.

◆ OPTIONAL: programmed ventricular stimulation

N/A Positive Negative

Positive if induction of sustained monomorphic VT lasting >30s or with
hemodynamic compromise

◆ Maximum 24 hours PVC count

Maximum number of PVCs in 24 hours registered by continuous ECG
monitoring (e.g. Holter)

◆ History of non-sustained VT

Yes No

Specified as a recorded ventricular tachycardia (>100bpm) ending
spontaneously within 30 seconds.

◆ Right ventricular ejection fraction (%)

50

As measured by cardiac MRI.



ARVC: kalkulátor rizika

<https://arvcrisk.com>

PATIENTS WITHOUT PRIOR
SUSTAINED VA

Risk of first sustained VA (any type), within:

5 years 2 years 1 year

Adjusted by PVS result (if available):

ALL PATIENTS WITH DEFINITE ARVC

I.e. regardless of prior sustained VA

Risk of fast VT(>250bpm)/VF/SCA, within:

5 years 2 years 1 year




consider the following: in those patients who have >15% 5-year risk, an ICD should be considered; in those patients with a 5% to 15% 5-year risk, an ICD may be considered; and in those with <5% 5-year risk, an ICD should generally be avoided. These risk

ARVC: kalkulátor rizika – genotyp ?

Importance of genotype for risk stratification in arrhythmogenic right ventricular cardiomyopathy using the 2019 ARVC risk calculator

554 jedinců s definitivní dg. ARVC, bez anamnézy setrvalé KT či SCD, 17 center ze 7 zemí

ARVC risk score performance varies by genotype






Závěr

- Je obtížné hovořit o samotné AF, ... když víme, že existuje ACM !

**O ACM vs. NDLVC na
XXVII. výroční konferenci ČASS,
která se uskuteční ve dnech 8.11.-9.11.2024
v hotelu Orea Resort Santon v Brně**





1. LÉKAŘSKÁ FAKULTA
UNIVERZITY KARLOVY V PRAZE



Děkuji za pozornost !




1. LÉKAŘSKÁ FAKULTA
UNIVERZITY KARLOVY V PRAZE





POZOR: „Pitfalls“ u MRI hodnocení ARVC

Apikolaterální bulging





Dle autorů citace: Izolovaná porucha kinetiky hrotu PK není typická pro ARVC



POZOR: „Pitfalls“ u MRI hodnocení ARVC

Butterfly apex



POZOR: „Pitfalls“ u MRI hodnocení ARVC

Tethering volné stěny PK

